Endorphins

Speaker 1...and this is where endorphins, our body's natural pain relievers, enter the conversation. We know they're released by things like exercise, but what about their long-term impact on aging and mortality when used as pain treatment?

Speaker 2It’s a complex picture. While endorphins are crucial for acute pain relief, long-term *opioid* use, which acts on the same pathways, raises questions. A study in *Public Health* (2024) found that chronic opioid use was associated with a 37% higher risk of all-cause mortality compared to short-term use.

Speaker 1That’s a significant statistic. And the risks seem to compound, right? I recall seeing something about combinations with other medications.

Speaker 2Exactly. Research in *Frontiers in Pharmacology* (2022) highlighted that opioid-gabapentinoid combination therapy was associated with a 2.76 times increased risk of CNS depression and mortality. These are serious concerns, especially for older adults.

Speaker 1So, on one hand, we have these potential long-term harms with opioid pathways. But what about the harm of *not* treating chronic pain? How does that factor into biological aging?

Speaker 2That’s the critical balance. Untreated chronic pain itself can accelerate biological aging. For example, *GeroScience* (2025) found painful diabetic neuropathy was linked to accelerated epigenetic aging and telomere shortening compared to painless neuropathy.

Speaker 1So, it's not simply a matter of avoiding medication. It’s about careful, supervised management. What’s still unknown, though, about endorphins and biological aging specifically?

Speaker 2We still need more direct evidence on how *endogenous* endorphin modulation, separate from exogenous opioids, impacts the epigenetic clock and all-cause mortality over decades. The link is mostly inferred from opioid research and the impact of chronic pain itself. The precise mechanisms and optimal strategies for long-term pain management to minimize overall mortality and aging effects remain areas of active research.

Speaker 1...and while endorphins are our body’s natural pain relievers, released through exercise or even pleasure, the conversation around their long-term impact, particularly with exogenous opioids mimicking them, often turns to all-cause mortality and aging.

Speaker 2Absolutely. It’s a nuanced area. For individuals with chronic, severe pain, opioids can provide necessary relief. But research from *Public Health* in 2024, for example, highlighted that chronic opioid use was associated with a higher risk of all-cause mortality compared to short-term use, with a hazard ratio of 1.37.

Speaker 1That’s a significant finding. And it becomes even more complex when combined with other medications. A *Frontiers in Pharmacology* study from 2022 pointed to opioid-gabapentinoid combination therapy potentially increasing the risk of CNS depression and mortality, showing an odds ratio of 2.76.

Speaker 2These are serious considerations for long-term safety. However, it's also critical to remember that untreated chronic pain isn't benign. *GeroScience* in 2025 reported that painful diabetic neuropathy is associated with accelerated epigenetic aging and telomere shortening compared with painless neuropathy. So, pain itself can accelerate biological aging.

Speaker 1Exactly. It's a balance. For some, carefully managed, supervised opioid use genuinely improves quality of life and prevents the harms of untreated pain. What's still uncertain, though, is the direct, causal relationship between endogenous endorphin levels and long-term mortality or aging in healthy individuals. The research often focuses on exogenous opioid use.

Speaker 2Right. We have strong data on pharmaceutical opioids, but less on whether boosting natural endorphins directly impacts longevity or reduces specific long-term harms in the same way. It’s an area needing more investigation.